The invention discloses an anti-SARS-CoV-2 fully humanized monoclonal antibody ZW2G10, the antibody has a unique CDR partition, and the antigen recognition epitope of the antibody is located in the RBD region of S1 protein. The EC50 of the antibody for neutralizing new coronavirus wild type pseudoviruses, Alpha pseudoviruses, Beta pseudoviruses, Gamma pseudoviruses, Delta pseudoviruses and Omicro pseudoviruses is 14.19 ng/mL, 14.12 ng/mL, 18.41 ng/mL, 15.59 ng/mL, 36.18 ng/mL and 19.26 ng/mL respectively. The ZW2G10 has broad-spectrum and high-efficiency neutralizing activity on the current main variant strain. The monoclonal antibody disclosed by the invention also has the characteristics of high expression, full human source and good stability, is suitable for industrial production, and has important application value for coping with outbreak and prevalence caused by new crown variants.